Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Other Non Operating Income (2018 - 2025)

Historic Other Non Operating Income for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$676000.0.

  • X4 Pharmaceuticals' Other Non Operating Income rose 6373.39% to -$676000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 731.22%. This contributed to the annual value of $1.9 million for FY2024, which is 7274.53% down from last year.
  • According to the latest figures from Q3 2025, X4 Pharmaceuticals' Other Non Operating Income is -$676000.0, which was up 6373.39% from $2.6 million recorded in Q2 2025.
  • X4 Pharmaceuticals' 5-year Other Non Operating Income high stood at $25.2 million for Q3 2023, and its period low was -$13.8 million during Q1 2024.
  • Its 5-year average for Other Non Operating Income is $2.3 million, with a median of $123000.0 in 2023.
  • Data for X4 Pharmaceuticals' Other Non Operating Income shows a peak YoY increase of 990742.57% (in 2024) and a maximum YoY decrease of 1128292.68% (in 2024) over the last 5 years.
  • Over the past 5 years, X4 Pharmaceuticals' Other Non Operating Income (Quarter) stood at $103000.0 in 2021, then plummeted by 3747.57% to -$3.8 million in 2022, then skyrocketed by 268.51% to $6.3 million in 2023, then tumbled by 142.14% to -$2.7 million in 2024, then skyrocketed by 74.66% to -$676000.0 in 2025.
  • Its last three reported values are -$676000.0 in Q3 2025, $2.6 million for Q2 2025, and $10.8 million during Q1 2025.